Syros Pharmaceuticals, Inc. (SYRS) Stock Price & Analysis
Syros Pharmaceuticals, Inc. (SYRS) closed at USD 0 on Wednesday, October 21, 2026, up 0.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 0; the Oct 21, 2026 session ranged USD 0–0 on volume of 904 shares. Market capitalization is $10,732, with a 52-week range of USD 0–0.02 (PNK). Source: Nexqual, retrieved October 23, 2026 at 10:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SYRS.md
Key facts (SYRS)
- Analysts: None (4 analysts), mean target USD 8.75 (range 4–20).
- Total return with dividends: 1Y -33.3% vs S&P 500 +14.9%; 5Y -100.0% vs S&P 500 +80.3%.
Analysts (SYRS)
Consensus None, 4 analysts; mean target USD 8.75 (low 4, high 20).
Total return (dividends reinvested) (SYRS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -33.3% | -100.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -33.4% | -90.1% |
| Volatility (annualized) | 1032.0% | 388.5% |
| Max drawdown | -96.7% (Sep 2026→Sep 2026) | -100.0% (Nov 2021→Sep 2025) |
SYRS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2024) | — | — | — | $0 | — |
| Next quarter (ends Mar 2025) | $-0.71 | $-0.75 | -5.8% | $0 | 3 |
| Current fiscal year (ends Dec 2024) | — | — | — | $0 | — |
| Next fiscal year (ends Dec 2025) | $-2.61 | $-2.26 | +15.2% | $0 | 4 |
Key Statistics (as of October 23, 2026 at 10:38 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.02 |
| Volume | 904 shares |
| Market Cap | $10,732 |
| Exchange | PNK |
Technical Analysis (SYRS)
Nexqual's technical model rates SYRS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 50 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (SYRS)
Wall Street analysts rate SYRS "None" based on 4 analysts, with a mean price target of USD 8.75 (range USD 4–20), per Nexqual as of October 23, 2026 at 10:38 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.75 |
| High Target | USD 20 |
| Low Target | USD 4 |
Earnings (SYRS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-09-30 | USD -0.16 vs est -0.67 ▲ beat |
| 2024-06-30 | USD -0.59 vs est -0.77 ▲ beat |
| 2024-03-31 | USD -0.1 vs est -0.94 ▲ beat |
| 2023-12-31 | USD -2.22 vs est -1.12 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financials & Fundamentals (SYRS)
| Total Revenue | $386,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -28891.71% |
| Profit Margin | +0.00% |
| ROE | -776.96% |
| Current Ratio | 2.25 |
| Total Cash | $58.27M |
| Total Debt | $60.23M |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Financial Health Score (SYRS)
Nexqual rates Syros Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:38 UTC.
| Growth | Critical — Revenue -33% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $58M cash vs $60M debt |
| Cash Flow | Weak — Operating cash flow -$100M (TTM) |
| Efficiency | Critical — ROE -777%, ROA -59.9% |
Ownership (SYRS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 26.83M |
| Float | 26.83M |
| Short % of Float | +17.01% |
Source: Nexqual, October 23, 2026 at 10:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt